drugset / Trial / NCT00752687
A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults
RandomizedParallel-groupQuadruple-blind
Summary
To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers and its anti-viral activity in HCV infected subjects.
Timeline
- Start
- 2008-09
- Primary completion
- 2009-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-072 | Small molecule | 10 mg | — |
| Subject | ABT-072 | Small molecule | 160 mg | — |
| Subject | ABT-072 | Small molecule | 320 mg | — |